Anticancer agent-361

Anticancer agent-361 (Compound 9d) (0.5-200 μM; 48 h) exhibits IC₅₀ = 3.57 μM against A549 cells, IC₅₀ = 3.77 μM against PANC-1 cells, IC₅₀ = 5.21 μM against PC-3 cells, and IC₅₀ = 6.07 μM against MCF-7 cells, with selectivity indices (SI) of 3.11, 2.94, 2.13, and 1.83, respectively, relative to HEK-293 cells^[1].
Anticancer agent-361 (IC₅₀ concentration; 48 h) induces G0/G1 phase arrest in A549, PANC-1, PC-3, and MCF-7 tumor cells, with a decreased proportion of cells in S phase; it selectively induces late apoptosis in tumor cells; it causes moderate LDH release from tumor cells, while LDH leakage from HEK-293 cells remains low, suggesting that membrane damage is a secondary change following apoptosis^[1].
Anticancer agent-361 exhibits favorable docking scores against PI3Kα, PI3Kγ, and RNR, with PI3Kα being the highest-scoring target, suggesting that PI3K inhibition is the more likely primary mechanism^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.